These are Some of The Top Companies to Watch in the Booming Psychedelics Industry June 18, 2020 - Baystreet.ca Some analysts peg the psychedelics industry with a $5 billion long-term valuation. In fact, such drugs are already proving to be a major game changer for millions of people all over the world. Already, countless studies have proven such drugs can treat a host of mental issues, like obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. That includes the 30 million Americans with eating disorders, highlighted by Eating Recovery Center. Better still, the medical community and even the US FDA are in support of psychedelics. Researchers from the University of California Davis for example found that micro-dosing with psychedelic drugs for a prolonged period of time showed promise. “Our study demonstrates that psychedelics can produce beneficial behavioral effects without drastically altering perception, which is a critical step towards producing viable medicines inspired by these compounds,” said David Olson of UC Davis, as quoted by Esquire. With such drugs a potential game-changer, some of the top companies to keep an eye on include The Yield Growth Corp. (CSE:BOSS)(OTC:BOSQF), Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM), Mind Medicine Inc. (OTC:MMEDF), Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF), and Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF). The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. announced that its majority owned subsidiary NeonMind has filed an additional provisional patent application related to using psychedelics as medicine. The most recent patent application, filed on June 17, 2020 covers the administration of DMT to treat compulsive eating disorder and other illnesses. DMT, or N,N-Dimethyltryptamine, is a derivative and structural analog of tryptamine. It is known as a hallucinogenic drug. It currently has no approved medical use, though DMT-containing plants are commonly used in indigenous Amazonian shamanic practice, and is sometimes found in the drink ayahuasca. DMT is found naturally in several plants including Mimosa tenuiflora, Diplopterys cabrerana, and Psychotria viridis. It is structurally similar to psilocin and its precursor psilocybin, a chemical found in so-called “magic mushrooms”. “DMT is a very interesting molecule that acts on the same type of serotonin receptors which are known to regulate appetite,” says Dr. William Panenka, Chair of the NeonMind Scientific Advisory Board. “As part of our overall patent strategy, we are establishing defensible intellectual property around multiple compounds that act on these receptors and intend to follow this with rigorous clinical trial work to establish efficacy.” The global projected market for weight loss and weight management treatment is estimated at USD $245 billion, according to MarketsandMarkets. The global projected market for diabetes treatment is estimated at $87 billion US Dollars, according to Modor Intelligence. Translational Life Sciences Inc. has a 20% interest as a co-collaborator on the development of NeonMind’s DMT related intellectual property. Other related developments from around the markets include: Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM) a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, since commencing trading on March 2, 2020 has expanded its initiatives and rapidly executed on such initiatives to position the Company as a leading publicly traded psychedelic medicine company developing novel rapid onset treatments for depression, post-traumatic stress disorder, and substance-use disorders via the clinical delivery of ketamine and ketamine-derivatives. The Company is pleased to share its corporate advancements and achievements over the last quarter, which target key segments in the psychedelics as medicines industry that will complement each other as the sector matures and accelerates. Mind Medicine Inc. (OTC:MMEDF) is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel’s Liechti Lab. The Phase 2 trial began recruiting patients in early January and has commenced treating patients with LSD. MindMed is the leading neuro-pharmaceutical company for psychedelic inspired medicines and previously formed an ongoing R&D collaboration with the University Hospital Basel’s Liechti Lab, the leading global clinical research laboratory for LSD, to evaluate multiple therapeutic uses of psychedelics and next-gen psychedelic therapies. This new development is part of the collaboration and Dr Matthias Liechti is serving as principal investigator of the clinical trial. Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF) specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an expansion to the sponsored research partnership agreement entered with the University of Wisconsin-Madison to evaluate novel formulations of psilocybin and a Phase 1 clinical study investigating the therapeutic application of psilocybin for an undisclosed addiction use disorder. “We are pleased to have expanded our research partnership with the University of Wisconsin-Madison in the development of novel psilocybin formulations that will serve as the platform to create unique psychedelic-based therapeutics for clinical research targeting specific medical needs, such as addiction use disorders,” said Michael Frank, Revive’s Chief Executive Officer. “As part of our psychedelic-based pharmaceutical strategy, we are focused on balancing research and development of novel psilocybin-based formulations and clinical research of psilocybin to create a robust product pipeline backed by intellectual property and clinical data with the aim to pursue the FDA regulatory pathway for commercialization. Revive plans to expand its clinical development pipeline with psilocybin for various addiction and dependence disorders.” Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF) announced the appointment of Roger C. Clinton, to the Advisory Board for its wholly owned subsidiary, Verrian GmbH. Clinton is active within the addiction treatment and specifically opiate addiction research sector, seeking to bring attention to the issue and enhance promising treatment options using psychedelics in conjunction with behavioral therapy through his global network. “I’m honored to be working with the team at Mota in a patient first approach. We believe the work that we’re doing can be transformative in people’s lives as they work daily to overcome addiction,” said Roger Clinton. On June 2nd, Mota announced the $20,000,000 acquisition of Verrian, a European pharmaceutical manufacturer of natural psilocybin extracts. Verrian is focused on psychedelic and cannabis treatments of opiate addiction. Clinton will play a vital role in advising and enhancing the patient perspective as well as helping to shape R&D efforts of our world-renowned addiction medicine experts, resulting in best of breed psychedelic derived treatments for the global marketplace. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of www.MarijuanaStox.com) and The Yield Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer. Contact Information: 2818047972 ty@MarijuanaStox.com
These are Some of The Top Companies to Watch in the Booming Psychedelics Industry June 18, 2020 - Baystreet.ca Some analysts peg the psychedelics industry with a $5 billion long-term valuation. In fact, such drugs are already proving to be a major game changer for millions of people all over the world. Already, countless studies have proven such drugs can treat a host of mental issues, like obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. That includes the 30 million Americans with eating disorders, highlighted by Eating Recovery Center. Better still, the medical community and even the US FDA are in support of psychedelics. Researchers from the University of California Davis for example found that micro-dosing with psychedelic drugs for a prolonged period of time showed promise. “Our study demonstrates that psychedelics can produce beneficial behavioral effects without drastically altering perception, which is a critical step towards producing viable medicines inspired by these compounds,” said David Olson of UC Davis, as quoted by Esquire. With such drugs a potential game-changer, some of the top companies to keep an eye on include The Yield Growth Corp. (CSE:BOSS)(OTC:BOSQF), Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM), Mind Medicine Inc. (OTC:MMEDF), Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF), and Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF). The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. announced that its majority owned subsidiary NeonMind has filed an additional provisional patent application related to using psychedelics as medicine. The most recent patent application, filed on June 17, 2020 covers the administration of DMT to treat compulsive eating disorder and other illnesses. DMT, or N,N-Dimethyltryptamine, is a derivative and structural analog of tryptamine. It is known as a hallucinogenic drug. It currently has no approved medical use, though DMT-containing plants are commonly used in indigenous Amazonian shamanic practice, and is sometimes found in the drink ayahuasca. DMT is found naturally in several plants including Mimosa tenuiflora, Diplopterys cabrerana, and Psychotria viridis. It is structurally similar to psilocin and its precursor psilocybin, a chemical found in so-called “magic mushrooms”. “DMT is a very interesting molecule that acts on the same type of serotonin receptors which are known to regulate appetite,” says Dr. William Panenka, Chair of the NeonMind Scientific Advisory Board. “As part of our overall patent strategy, we are establishing defensible intellectual property around multiple compounds that act on these receptors and intend to follow this with rigorous clinical trial work to establish efficacy.” The global projected market for weight loss and weight management treatment is estimated at USD $245 billion, according to MarketsandMarkets. The global projected market for diabetes treatment is estimated at $87 billion US Dollars, according to Modor Intelligence. Translational Life Sciences Inc. has a 20% interest as a co-collaborator on the development of NeonMind’s DMT related intellectual property. Other related developments from around the markets include: Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM) a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, since commencing trading on March 2, 2020 has expanded its initiatives and rapidly executed on such initiatives to position the Company as a leading publicly traded psychedelic medicine company developing novel rapid onset treatments for depression, post-traumatic stress disorder, and substance-use disorders via the clinical delivery of ketamine and ketamine-derivatives. The Company is pleased to share its corporate advancements and achievements over the last quarter, which target key segments in the psychedelics as medicines industry that will complement each other as the sector matures and accelerates. Mind Medicine Inc. (OTC:MMEDF) is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel’s Liechti Lab. The Phase 2 trial began recruiting patients in early January and has commenced treating patients with LSD. MindMed is the leading neuro-pharmaceutical company for psychedelic inspired medicines and previously formed an ongoing R&D collaboration with the University Hospital Basel’s Liechti Lab, the leading global clinical research laboratory for LSD, to evaluate multiple therapeutic uses of psychedelics and next-gen psychedelic therapies. This new development is part of the collaboration and Dr Matthias Liechti is serving as principal investigator of the clinical trial. Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF) specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an expansion to the sponsored research partnership agreement entered with the University of Wisconsin-Madison to evaluate novel formulations of psilocybin and a Phase 1 clinical study investigating the therapeutic application of psilocybin for an undisclosed addiction use disorder. “We are pleased to have expanded our research partnership with the University of Wisconsin-Madison in the development of novel psilocybin formulations that will serve as the platform to create unique psychedelic-based therapeutics for clinical research targeting specific medical needs, such as addiction use disorders,” said Michael Frank, Revive’s Chief Executive Officer. “As part of our psychedelic-based pharmaceutical strategy, we are focused on balancing research and development of novel psilocybin-based formulations and clinical research of psilocybin to create a robust product pipeline backed by intellectual property and clinical data with the aim to pursue the FDA regulatory pathway for commercialization. Revive plans to expand its clinical development pipeline with psilocybin for various addiction and dependence disorders.” Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF) announced the appointment of Roger C. Clinton, to the Advisory Board for its wholly owned subsidiary, Verrian GmbH. Clinton is active within the addiction treatment and specifically opiate addiction research sector, seeking to bring attention to the issue and enhance promising treatment options using psychedelics in conjunction with behavioral therapy through his global network. “I’m honored to be working with the team at Mota in a patient first approach. We believe the work that we’re doing can be transformative in people’s lives as they work daily to overcome addiction,” said Roger Clinton. On June 2nd, Mota announced the $20,000,000 acquisition of Verrian, a European pharmaceutical manufacturer of natural psilocybin extracts. Verrian is focused on psychedelic and cannabis treatments of opiate addiction. Clinton will play a vital role in advising and enhancing the patient perspective as well as helping to shape R&D efforts of our world-renowned addiction medicine experts, resulting in best of breed psychedelic derived treatments for the global marketplace. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of www.MarijuanaStox.com) and The Yield Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer. Contact Information: 2818047972 ty@MarijuanaStox.com